Evotec 2025 Outlook: Revenues To Grow 5%-10%, Reaching €840M-€880M (Vs. €879.457M Est.), Sees Adj. EBITDA Of €30M-€50M; For 2028 Outlook, Expects 8%-12% CAGR And An EBITDA Margin Above 20%

Benzinga
17 Apr

Guidance for full-year 2025

Group revenues expected in the range of € 840 - 880 m (2024: € 797.0 m)

R&D expenditures are expected in a range of € 40 - 50 m (2024: € 50.8 m)

Adjusted Group EBITDA is expected to reach € 30 - 50 m (2024: € 22.6 m)

Outlook 2028

Group revenues CAGR 2024-2028 targeted to be in a range of 8 - 12 %

Adj. EBITDA margin 2028 expected to be above 20 %

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10